Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

dual tasking

- PMLiVE

Two drugs found to reduce mortality in severe COVID-19 patients

Actemra and Kevzara also improved recovery times among critically ill COVID-19 patients

- PMLiVE

Q&A: Shairose Ebrahim

PME interviews integrated medhealth communication (imc) group's President and CEO

Importance of Emotional Intelligence in Pharma and Medical Affairs

Emma Lynch, Founder of EQ Vibration & Quadrant 2 Medical, delves into a number of interesting topics such as the importance of emotional intelligence, patient-centric solutions, and adopting a growth...

Impetus Digital

- PMLiVE

CureVac and Bayer partner on mRNA-based COVID-19 vaccine

German pharma giant will support further development of CVnCoV

- PMLiVE

EMA recommends authorisation of Moderna’s COVID-19 vaccine

European Commission likely to formally approve the vaccine soon

- PMLiVE

Three ways AI will change healthcare in the next decade

Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives

- PMLiVE

Moderna wins EU authorisation for COVID-19 vaccine

EU Commission approval comes on the same day as positive CHMP opinion

- PMLiVE

Pfizer introduces new logo in a ‘shift from commerce to science’

First major rebranding in 70 years for pharma giant

- PMLiVE

Kite and Oxford BioTherapeutics sign oncology research pact

Agreement will focus on five novel drug targets across a range of indications

- PMLiVE

AZ/Oxford University COVID-19 vaccine wins emergency approval in India

In June 2020, AZ signed a licensing deal with the Serum Institute for the vaccine

- PMLiVE

Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation

Swiss pharma is aiming for approval in first-line NSCLC

Biogen Idec building

New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU

New administration offers same efficacy as subcutaneous injection

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links